top of page

About VitalTE Life Sciences 

We started in 2019, founded by a surgical physician who went on to treat over 15,000 patients with hormone deficiencies and invented the Atrocar for surgical pellet-based testosterone delivery.

​

Our next step in the journey is the VIT-200 Testosterone Injectable Microspheres - the potential for a new "Standard of Care" through accelerated 505(b)(2) pathway

 

Our vision is safer therapeutic delivery, increased convenience & reliable compliance.

Founder, Dr. Charles Virden attended Occidental College for his undergraduate years to earn a Bachelor of Applied Science (BASc) in biology. He went to medical school at the University of Southern California, Keck School of Medicine. In 1987, he graduated from the University of Southern California with a medical degree. Dr. Virden completed his general surgery internship and residency at the University of California, San Diego, CA in 1993. He also completed a research fellowship and residency in plastic surgery at the University of California in San Diego, CA. Dr. Virden moved to Reno, NV in 1995 to open his private practice.

​

We want to provide you with my total commitment in all aspects of your care. We appreciate your confidence, and we want to create an experience for you that will be equally rewarding. We are committed to educating you about your particular concern and offer you the highest level of care in a friendly and caring environment. We consider it a privilege to have the opportunity to serve you.

Our Story

Executive Leadership Team

drvirden-large.webp

Charles Virden

Founder / Chief Executive Officer

  • Treated 40,000 surgical patients

  • 7,000 hormone patients

  • Inventor and patent holder of the state of the Atrocar Medical Device

  • Double Board Certified

1663094196886-1.jpg

Matt Virden

Co-Founder / Chief Business Officer

  • 10 years in cash clinical initiatives

  • 15 years in medical office dynamics

  • 1 successful business start, growth, and sale

eric.jpg

Eric Kizior

Chief Strategic Officer

  • Over 25 years of experience in the Pharmaceutical Industry

  • Commercial Experience: 15 Diseases, 20+
    Products

  • Executive Roles: Commercial Sales / Marketing / Operations / Business
    Development

  • Novartis, Benuvia, Likarda

Geoff Fatzinger.png

Geoff Fatzinger

Chief Regulatory Officer

  • Chief Strategic Officer and global
    SME in Regulatory Affairs & Product
    Development

  • Driving Innovation at the Intersection of Health Tech and Regulatory Excellence

Doug Bryans.png

Doug Bryans

Chief Manufacturing Officer

  • Over 25 years of experience in contract.

  • Chief Executive Office at Bryallan LLC

  • General Manager at Catalent Pharma
    Solutions

  • VP Global Technical Operations at

  • Cardinal Health Pharmaceutical
    Technology and Services

Scientific Advisory Board

lisa.png

Lisa Stehno-Bittel

PhD

  • Founder & President of Likarda, a biotech company focused on advanced hydrogel delivery systems

  • Former KU Medical Center professor, department chair, and professor emerita

  • Began career as a physical therapist; PhD in physiology; Mayo pharmacology fellowship

  • 30+ years in diabetes, islet biology, cell therapy, and translational medicine

  • Developed KU-based 3D cell culture/islet platform, including Kanslets™

  • Led Likarda’s evolution into tunable hydrogel microsphere and Core Shell Spherification technology

  • Author of 90+ peer-reviewed publications and recipient of $9M+ in research funding

  • Recognized as an AIMBE Fellow and National Academy of Inventors Senior Member for innovation and commercialization

robert.png

Robert Seik

PharmD, MBA, FMNM

  • PharmD from Duquesne University with clinical training focused on Infectious disease & Outcomes research

  • Fellow in Metabolic & Nutritional Medicine with the American Academy of Anti-Aging Medicine (A4M)

  • Contributed to research and marketing of novel therapies for Infectious diseases & Rare immune disorders

  • During MBA studies (2003), analyzed the coming 2010 pharmaceutical patent cliff and the industry shift toward Biologics (monoclonal antibodies), Immune response modifiers, Vaccines

  • Entrepreneurial background: Owned and successfully exited a large compounding pharmacy in Las Vegas after ~20 years

  • Experienced medical lecturer, teaching clinicians about evidence-based hormone replacement using subcutaneous pellet implants

  • Schering-Plough, InterMune, and Valeant Pharmaceuticals

david.png

David Bieber

DVM

  • Veterinarian and founder of Sheridan West Animal Clinic; veterinary training included the University of Pisa, internships at University of Pennsylvania and Animal Medical Center, then South Florida emergency/surgery practice.

  • Developer of Dogosterone™ Therapy, a testosterone-restoration approach for spayed/neutered dogs with mobility, muscle, joint, and quality-of-life issues; clinic materials say he began researching it in 2008 and offering it in 2009.

  • Published/marketed clinical experience: IVC Journal article reports 140+ treated canines, a claimed 95% success rate, and a 2011–2018 group of 38 spayed/neutered dogs, with 36 of 38 reportedly improving after TRT.

  • Commercialization model includes Dogosterone veterinarian certification/training, with IVC reporting an online curriculum, competency test, and AAVSB RACE certification.

  • Testosterone animal IP: US20140371189A1, “Testosterone replacement therapy in animals, including dogs”

bottom of page